P3 HEALTH PARTNERS INC

Company Overview

P3 Health Partners Inc. is a physician‑led, population health management company focused on value‑based care primarily in the Medicare Advantage (MA) market. Organized in an Up‑C structure, P3 Health Partners is the sole manager and ~45% direct owner of P3 LLC, which holds substantially all operating assets; the business delivers care under capitated and PMPM contracts and operates a proprietary P3 Technology/Health Hub to aggregate clinical and claims data. Operations concentrate in Arizona, California, Nevada and Oregon, with ~360 employees, ~3,100 contracted PCPs and a heavy reliance on four payors that drove ~59–60% of capitated revenue in 2024. The business is highly seasonal (membership and RAF realization spike after the Medicare Annual Enrollment Period in Q1) and currently faces material liquidity, medical‑cost and covenant risks after rapid growth that produced large GAAP and Adjusted EBITDA losses in 2024–2025.

Executive Compensation Practices

Executive pay at P3 is likely to be heavily weighted toward commercial and clinical performance metrics rather than pure revenue growth, with the most relevant metrics being at‑risk membership growth/retention, per‑member‑per‑month (PMPM) revenue and RAF/risk‑adjustment capture, medical margin/medical expense control, and adjusted EBITDA or cash flow improvement. Given the company’s Up‑C ownership, physician leadership and reliance on payor contracts, compensation mixes may include management fees or distributions tied to P3 LLC economics, short‑term bonuses for membership and RAF realization, and long‑term equity or unit awards intended to align executives with multi‑year platform scale and quality outcomes; however, equity will be sensitive to dilution from ongoing financings (shelf/ATM) and the April 2025 1‑for‑50 reverse split. The near‑term emphasis from management’s disclosures — covenant compliance, liquidity raises and cost control — means incentive design is likely to include covenant‑based performance gates, deferred payouts or clawbacks, and compliance/quality hurdles to limit regulatory risk.

Insider Trading Considerations

Insider trading activity at P3 will be heavily influenced by cadence and event risk specific to MA: membership and RAF updates (especially around Q1/AEP), payor contract wins/terminations, quarterly filings that revise IBNR/premium deficiency reserves, and financings or asset sales that materially change liquidity. The company’s tight cash position (~$38M cash) and substantial debt (including a Term Loan maturing Dec‑2025 and high‑rate subordinated promissory notes) create incentives for insiders to seek liquidity, but trades will be governed by standard securities rules (Section 16 short‑swing rules for officers/directors, Form 4 disclosure) and commonly by pre‑arranged 10b5‑1 plans to manage legal risk. In addition, healthcare regulatory exposures (AKS, Stark, FCA, HIPAA and state rules) can trigger compliance‑related blackout periods or clawbacks and raise the reputational and enforcement stakes of any suspicious insider sales around adverse disclosures. Investors should watch patterns of option exercises, insider sales into ATM offerings, and timing of trades around AEP, payor announcements and covenant notices for signals of management’s view on liquidity and near‑term prospects.